Physician profile
Sofia Maite Dominguez
NPI 1699317123
$5,975.44
in general payments reported to CMS, 2019-2025
26 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.38 · 2022: $1,517 · 2023: $1,492 · 2024: $1,388 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,443.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,232.95 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $689.89 | 2022-2025 | |
| Amgen INC. | $663.21 | 2022-2025 | Enbrel, Otezla, Evenity |
| Ucb, INC. | $517.20 | 2022-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $450.53 | 2022-2025 | Benlysta |
| Radius Health, INC. | $373.07 | 2022-2025 | |
| Lilly USA, LLC | $364.61 | 2022-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $293.48 | 2022-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $236.05 | 2022-2025 | Lupkynis |
| Pfizer INC. | $213.36 | 2022-2025 | |
| Depuy Synthes Sales INC. | $149.88 | 2022-2024 | Orthovisc, Monovisc |
| Janssen Biotech, INC. | $122.45 | 2024-2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $101.25 | 2024-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $95.26 | 2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $90.86 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $78.62 | 2021-2025 | Renflexis, Hadlima |
| Sobi, INC | $51.90 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $50.69 | 2022-2024 | Saphnelo |
| Bioventus LLC | $39.73 | 2022-2025 | Xcell |
| Alexion Pharmaceuticals, INC. | $31.02 | 2024 | Strensiq |
| Atricure, INC. | $27.65 | 2025 | Atricure Cryoice Cryoablation System (Cryo2) |
| Sandoz INC. | $22.07 | 2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $21.60 | 2024 | Idacio |
| Kiniksa Pharmaceuticals, LTD. | $20.69 | 2022 | |
| Genentech USA, INC. | $20.50 | 2023 | Actemra |
| Alvogen INC | $16.92 | 2023 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.